Wallen J W, Cate R L, Kiefer D M, Riemen M W, Martinez D, Hoffman R M, Donahoe P K, Von Hoff D D, Pepinsky B, Oliff A
Department of Cancer Research, Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486.
Cancer Res. 1989 Apr 15;49(8):2005-11.
Múllerian Inhibiting Substance (MIS) is a testicular hormone that promotes involution of the Múllerian duct during embryogenesis. The Múllerian duct gives rise to adult female reproductive ducts including the fallopian tubes, uterus, and upper vagina. Thus, testicular MIS ensures the regression of female sex organ primordia. Partially purified bovine MIS was reported to inhibit proliferation of tumor cells derived from human gynecological cancers. These observations suggest that MIS might be an effective anticancer agent for some human tumors. Recombinant human MIS (rHu-MIS) has recently become available. To assess the antiproliferative activity of rHu-MIS, we examined its effects on 11 ovarian, six endometrial, and two nongynecological human tumor cell lines. rHu-MIS had no effect on proliferation of these cell lines in five independent assays. Forty-three primary human tumor explants were also examined in human tumor colony forming assays, gel-supported primary culture assays, and subrenal capsule assays. rHu-MIS significantly inhibited the growth of five of these tumors including four ovarian and one small cell lung cancer explant. The four ovarian cancer responses include three of 13 (23%) explants tested in human tumor colony-forming assays and one of eight (12.5%) explants tested in gel-supported primary culture assays. We conclude that rHu-MIS may have antiproliferative activity against some human ovarian cancers.
苗勒管抑制物质(MIS)是一种睾丸激素,在胚胎发育过程中促进苗勒管退化。苗勒管发育为成年女性的生殖管道,包括输卵管、子宫和阴道上段。因此,睾丸MIS可确保女性性器官原基退化。据报道,部分纯化的牛MIS可抑制源自人类妇科癌症的肿瘤细胞增殖。这些观察结果表明,MIS可能是某些人类肿瘤的有效抗癌剂。重组人MIS(rHu-MIS)最近已可获得。为评估rHu-MIS的抗增殖活性,我们检测了其对11种卵巢、6种子宫内膜和2种非妇科人类肿瘤细胞系的影响。在5项独立试验中,rHu-MIS对这些细胞系的增殖无影响。我们还在人类肿瘤集落形成试验、凝胶支持的原代培养试验和肾包膜下试验中检测了43个原发性人类肿瘤外植体。rHu-MIS显著抑制了其中5种肿瘤的生长,包括4种卵巢癌和1种小细胞肺癌外植体。4例卵巢癌反应包括在人类肿瘤集落形成试验中检测的13个外植体中的3个(23%)和在凝胶支持的原代培养试验中检测的8个外植体中的1个(12.5%)。我们得出结论,rHu-MIS可能对某些人类卵巢癌具有抗增殖活性。